Skip to main content

Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product
    bamlanivimab etesevimab
    casirivimab imdevimab
    Health Outcome(s)

    This analysis is part of the ongoing effort to monitor the utilization of outpatient COVID-19 treatment under emergency use authorization (EUA). In this request we examined use of monoclonal antibodies (mAb) in the Rapid COVID Sentinel Distributed Database (SDD). This request had three Aims:

    • Aim 1: Characterize mAb users, mAb non-users, and COVID-19 patients
    • Aim 2: Estimate rates of hospitalization following outpatient mAb use
    • Aim 3: Estimate rates of anaphylaxis following mAb use

    The study period for Aims 1 and 2 includes data from November 9, 2020 up to June 30, 2021. The study period for Aim 3 includes data from November 9, 2020 up to September 30, 2021 (most recent available data). We distributed this request to six Sentinel Rapid COVID Data Partners on December 27, 2021.